The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., MACFARLANE, J. D., Antoni, C., Leeb, B. F., Elliott, M. J., Woody, J. N., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w · Cited by 1,623
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Antibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Bartelds, G. M. (2011) · JAMA · doi:10.1001/jama.2011.406 · Cited by 782
Aalberse, R. C., van der Gaag, R., & van Leeuwen, J. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.130.2.722 · Cited by 736
van de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W., Todesco, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 617
Immunogenicity of therapeutic proteins: Clinical implications and future prospects
Schellekens, H. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80075-3 · Cited by 556
Glycosylation of Recombinant Antibody Therapeutics
Jefferis, R. (2008) · Biotechnology Progress · doi:10.1021/bp040016j · Cited by 526
Lusher, J. M., Arkin, S., Abildgaard, C. F., & Schwartz, R. S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302183280701 · Cited by 476
Wolbink, G. J., Vis, M., Lems, W., Voskuyl, A. E., De Groot, E., Nurmohamed, M. T., Stapel, S., Tak, P. P., Aarden, L., & Dijkmans, B. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21671 · Cited by 471
Self-citationBendtzen, K., Geborek, P., Svenson, M., Larsson, L., Kapetanovic, M. C., & Saxne, T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22214 · Cited by 384
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
Baker, M., Reynolds, H. M., Lumicisi, B., & Bryson, C. J. (2010) · Self/Nonself · doi:10.4161/self.1.4.13904 · Cited by 372
[Etanercept for therapy of rheumatoid arthritis].
Miyasaka, N. (2005) · PubMed · Cited by 367
Characterizing biological products and assessing comparability following manufacturing changes
Chirino, A. J., & Mire-Sluis, A. (2004) · Nature Biotechnology · doi:10.1038/nbt1030 · Cited by 364
Gl, B., Gomperts, E. D., Courter, S. G., Gruppo, R. A., Em, G., Manco‐Johnson, M. J., Shapiro, A. D., Scheibel, E., White, G. C., & Lee, M. (1994) · PubMed · doi:10.1182/blood.v83.9.2428.bloodjournal8392428 · Cited by 346
Fleischmann, R., Vencovsky, J., van Vollenhoven, R. F., Borenstein, D., Box, J., Coteur, G., Goel, N., Brezinschek, H.-P., Innes, A., & Strand, V (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.099291 · Cited by 338
Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
Chirmule, N., Jawa, V., & Meibohm, B. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9340-y · Cited by 335
Factors influencing the immunogenicity of therapeutic proteins
Schellekens, H. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh1092 · Cited by 332
Koren, E., Smith, H. W., Shores, E., Shankar, G., Finco-Kent, D., Rup, B., Barrett, Y.-C., Devanarayan, V., Gorovits, B., Gupta, S., et al. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2008.01.001 · Cited by 328
Jacobi, A. M., Reiter, K., Mackay, M., Aranow, C., Hiepe, F., Radbruch, A., Hansen, A., Burmester, G., Diamond, B., Lipsky, P. E., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23498 · Cited by 289
Mitoma, H., Horiuchi, T., Hatta, N., Tsukamoto, H., Harashima, S.-I., Kikuchi, Y., Otsuka, J., Okamura, S., Fujita, S., & Harada, M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.060 · Cited by 270
Antibody humanization: a case of the ‘Emperor’s new clothes’?
Clark, M. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01680-7 · Cited by 258
Pascual-Salcedo, D., Plasencia, C., Ramiro, S., Nuno, L., Bonilla, G., Nagore, D., Ruiz del Agua, A., Martinez, A., Aarden, L., Martin-Mola, E., et al. (2011) · Rheumatology · doi:10.1093/rheumatology/ker124 · Cited by 256
Ross, C., Clemmesen, K. M., Svenson, M., S�rensen, P. S., Koch‐Henriksen, N., Skovgaard, G. L., Bendtzen, K., & the Danish Multiple Sclerosis Study Group (2000) · Annals of Neurology · doi:10.1002/1531-8249(200011)48:5<706::aid-ana3>3.0.co;2-v · Cited by 243
Vultaggio, A., Matucci, A., Nencini, F., Pratesi, S., Parronchi, P., Rossi, O., Romagnani, S., & Maggi, E. (2010) · Allergy · doi:10.1111/j.1398-9995.2009.02280.x · Cited by 238
Tsutsumi, Y., Onda, M., Nagata, S., Lee, B., Kreitman, R. J., & Pastan, I. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.140210597 · Cited by 216
Choy, E. H. S. (2002) · Rheumatology · doi:10.1093/rheumatology/41.10.1133 · Cited by 213
van Schouwenburg, P. A., van de Stadt, L. A., de Jong, R. N., van Buren, E. E. L., Kruithof, S., de Groot, E., Hart, M., van Ham, S. M., Rispens, T., Aarden, L., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201445 · Cited by 203
Self-citationBen-Horin, S., Yavzori, M., Katz, L., Kopylov, U., Picard, O., Fudim, E., Coscas, D., Bar-Meir, S., Goldstein, I., & Chowers, Y. (2011) · Gut · doi:10.1136/gut.2009.201533 · Cited by 203
Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles
Anderson, P. J. (2005) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.01.005 · Cited by 202
Genovese, M. C., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., Valente, R., Nash, P., Simon‐Campos, J. A., Porawska, W., Box, J., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30463 · Cited by 196
Rosendaal, F., Nieuwenhuis, H., van den Berg, H., Heijboer, H., Mauser- Bunschoten, E., van der Meer, J., Smit, C., Strengers, P., & Briet, E. (1993) · Blood · doi:10.1182/blood.v81.8.2180.2180 · Cited by 194
Zhou, H., Jang, H., Fleischmann, R. M., Bouman‐Thio, E., Xu, Z., Marini, J. C., Pendley, C., Jiao, Q., Shankar, G., Marciniak, S. J., et al. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006298188 · Cited by 191
Svenson, M., Geborek, P., Saxne, T., & Bendtzen, K. (2007) · Rheumatology · doi:10.1093/rheumatology/kem261 · Cited by 189
ANTI-IDIOTYPIC AND NON-ANTI-INDIOTYPIC ANTIBODIES TO OKT3 ARISING DESPITE INTENSE IMMUNOSUPPRESSION
Jaffers, G. J., Fuller, T. C., Cosimi, A. B., Russell, P. S., Winn, H. J., & Colvin, R. B. (1986) · Transplantation · doi:10.1097/00007890-198605000-00004 · Cited by 185
Hermeling, S., Schellekens, H., Maas, C., Gebbink, M. F. B. G., Crommelin, D. J. A., & Jiskoot, W. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20599 · Cited by 185
van der Laken, C. J., Voskuyl, A. E., Roos, J. C., Stigter van Walsum, M., de Groot, E. R., Wolbink, G., Dijkmans, B. A. C., & Aarden, L. A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.057406 · Cited by 184
Self-citationHuman Immune Response to Recombinant Human Proteins
Porter, S. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200101)90:1<1::aid-jps1>3.0.co;2-k · Cited by 183
Prescott, R., Nakai, H., Saenko, E. L., Scharrer, I., Nilsson, I. M., Humphries, J. E., Hurst, D., Bray, G., Scandella, D., & Groups, T. R. A. K. S. (1997) · Blood · doi:10.1182/blood.v89.10.3663 · Cited by 183
LUSHER, J. M., ARKIN, S., ABILGAARD, C. F., & SCHWARTZ, R. S. (1993) · Survey of Anesthesiology · doi:10.1097/00132586-199310000-00058 · Cited by 181
Jamnitski, A., Bartelds, G. M., Nurmohamed, M. T., van Schouwenburg, P. A., van Schaardenburg, D., Stapel, S. O., Dijkmans, B. A. C., Aarden, L., & Wolbink, G. J. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.135111 · Cited by 178
Self-citationAarden, L., Ruuls, S. R., & Wolbink, G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.011 · Cited by 175
Self-citationBrusic, V., Bajic, V. B., & Petrovsky, N. (2004) · Methods · doi:10.1016/j.ymeth.2004.06.006 · Cited by 166
van Schouwenburg, P. A., Bartelds, G. M., Hart, M. H., Aarden, L., Wolbink, G. J., & Wouters, D. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.09.005 · Cited by 163
Self-citationDifferential effect of drug interference in immunogenicity assays
Hart, M. H., de Vrieze, H., Wouters, D., Wolbink, G.-J., Killestein, J., de Groot, E. R., Aarden, L. A., & Rispens, T. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.07.019 · Cited by 160
Self-citationImmunogenicity of therapeutic proteins
Schellekens, H. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg164 · Cited by 148
Miyasaka, N., & The CHANGE Study Investigators (2008) · Modern Rheumatology · doi:10.1007/s10165-008-0045-0 · Cited by 144
Dore, R. K., Mathews, S. D., Schechtman, J., et al. (2007) · PubMed · Cited by 144
Rojas, J. R., Taylor, R. P., Cunningham, M. R., Rutkoski, T. J., Vennarini, J., Jang, H., Graham, M. A., Geboes, K. J., Rousselle, S. D., & Wagner, C. L. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.079277 · Cited by 130
Vennegoor, A., Rispens, T., Strijbis, E. M. M., Seewann, A., Uitdehaag, B. M. J., Balk, L. J., Barkhof, F., Polman, C. H., Wolbink, G., & Killestein, J. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512460604 · Cited by 126
Self-citationChinol, M., Casalini, P., Maggiolo, M. J., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.463 · Cited by 123
Korswagen, L.-A., Bartelds, G. M., Krieckaert, C. L. M., Turkstra, F., Nurmohamed, M. T., van Schaardenburg, D., Wijbrandts, C. A., Tak, P. P., Lems, W. F., Dijkmans, B. A. C., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30209 · Cited by 121
Self-citationThe Human Immune Response to the OKT3 Monoclonal Antibody Is Oligoclonal
Chatenoud, L., Jonker, M., Villemain, F., Goldstein, G., & Bach, J. (1986) · Science · doi:10.1126/science.3086976 · Cited by 98
Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease
Candon, S., Mosca, A., Ruemmele, F. M., Goulet, O., Chatenoud, L., & Cézard, J. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.07.010 · Cited by 95
Kohno, T., Tam, L. T., Stevens, S. R., & Louie, J. S. (2007) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/sj.jidsymp.5650034 · Cited by 91
Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII
JONES, T. D., Phillips, W. J., Smith, B. J., BAMFORD, C. A., Nayee, P. D., Baglin, T. P., Gaston, H., & Baker, M. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01309.x · Cited by 90
Magdelaine–Beuzelin, C., Vermeire, S., Goodall, M. D., Baert, F., Noman, M., Assche, G. V., Ohresser, M. C. P., Degenne, D., Dugoujon, J., Jefferis, R., et al. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832a06bf · Cited by 88
Mayer, A., Sharma, S. K., Tolner, B., Minton, N. P., Purdy, D., Amlot, P. L., Tharakan, G., Beǵent, R. H. J., & Chester, K. A. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601888 · Cited by 84
Yeung, V. P., Chang, J., Miller, J., Barnett, C., Stickler, M. M., & Harding, F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.6658 · Cited by 81
Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo
Moise, L., Song, C. H., Martin, W. D., Tassone, R., Groot, A. S. D., & Scott, D. W. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.11.010 · Cited by 80
O’Mahony, D., & Bishop, M. R. (2006) · Frontiers in bioscience · doi:10.2741/1909 · Cited by 77
Immunogenicity of biological therapeutics: from assay to patient
Krieckaert, C. L. M., Rispens, T., & Wolbink, G. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283521c4e · Cited by 73
Self-citationA Novel Strategy To Reduce the Immunogenicity of Biological Therapies
Somerfield, J., Hill-Cawthorne, G. A., Lin, A., Zandi, M. S., McCarthy, C., Jones, J., Willcox, M., Shaw, D. M., Thompson, S. A. J., Compston, A., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000422 · Cited by 72
Bartelds, G. M., de Groot, E. R., Nurmohamed, M. T., Hart, M. H. L., van Eede, P. H., Wijbrandts, C. A., Crusius, J. B. A., Dijkmans, B. A. C., Tak, P. P., Aarden, L. A., et al. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3208 · Cited by 71
Self-citationIgG4 Production Against Adalimumab During Long Term Treatment of RA Patients
van Schouwenburg, P. A., Krieckaert, C. L. M., Nurmohamed, M. T., Hart, M. H. L., Rispens, T., Aarden, L. A., Wouters, D., & Wolbink, G. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9705-0 · Cited by 69
Self-citationCarpenter, J. P., Cherney, B., Lubinecki, A., Ma, S., Marszal, E., Mire‐Sluis, A. R., Nikolai, T. J., Novak, J. M., Ragheb, J. A., & Šimák, J. (2010) · Biologicals · doi:10.1016/j.biologicals.2010.07.002 · Cited by 67
Kim, M.-S., Lee, S., Song, M.-Y., Yoo, T. H., Lee, B.-K., & Kim, Y. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.10.034 · Cited by 66
Rathanaswami, P., Roalstad, S., Roskos, L. K., Su, Q. J., Lackie, S. J., & Babcook, J. S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.002 · Cited by 64
Petitpain, N., Gambier, N., Wahl, D. G., Chary-Valckenaere, I., Lœuille, D., & Gillet, P. (2009) · Bio-Medical Materials and Engineering · doi:10.3233/bme-2009-0600 · Cited by 63
Correlation between Factor VIII Genotype and Inhibitor Development in Hemophilia A
Fakharzadeh, S. S., & Kazazian, H. H. (2000) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2000-9819 · Cited by 55
Parker, E. T., Healey, J. F., Barrow, R. T., Craddock, H. N., & Lollar, P. (2004) · Blood · doi:10.1182/blood-2003-11-3891 · Cited by 51
A Survey of Applications of Biological Products for Drug Interference of Immunogenicity Assays
Wang, Y., Fang, L., Zhou, L., Wang, J., & Ahn, H. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0833-2 · Cited by 48
Assessment of the antigenic response in humans to a recombinant mutant interferon beta
Konrad, M. W., Childs, A., Merigan, T. C., & Borden, E. C. (1987) · Journal of Clinical Immunology · doi:10.1007/bf00917014 · Cited by 46
Unresolved issues in biologic therapy for rheumatoid arthritis
van Vollenhoven, R. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.22 · Cited by 44
Prevention and prediction of inhibitor risk
Astermark, J. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02827.x · Cited by 36
Christen, U., Thuerkauf, R., Stevens, R. M., & Lesslauer, W. (1999) · Human Immunology · doi:10.1016/s0198-8859(99)00068-3 · Cited by 34
Requirements for immune recognition and processing of factor VIII by antigen-presenting cells
van Haren, S. D., Wroblewska, A., Fischer, K., Voorberg, J., & Herczenik, E. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.10.001 · Cited by 23
Silva, H. M., Moraes‐Vieira, P. M., Costa, P., Pimentel, B. M. S., Moro, A. M., Kalil, J. E., Maranhão, A. Q., Coelho, V. P. C. V., & Brígido, M. M. (2009) · Immunology Letters · doi:10.1016/j.imlet.2009.06.009 · Cited by 18
Cited by
Regulation of tumour necrosis factor signalling: live or let die
Brenner, D., Blaser, H., & Mak, T. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3834 · Cited by 998
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Lin, Y.-J., Anzaghe, M., & Schülke, S. (2020) · Cells · doi:10.3390/cells9040880 · Cited by 932
Sedger, L. M., & McDermott, M. F. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.016 · Cited by 771
Tocilizumab: A review in rheumatoid arthritis
Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-017-0829-7 · Cited by 419
Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes
Krishna, M., & Nadler, S. G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00021 · Cited by 389
Metadata
- Authors
- van Schouwenburg, P. A., Rispens, T., & Wolbink, G. J.
- Venue
- Nature Reviews Rheumatology
- Published
- 2013-02-12
- Volume
- 9
- Issue
- 3
- Pages
- 164-172
- ISSN
- 1759-4790 (ISSN-L)
- 1759-4804
- OpenAlex
- W2024148297
- Cited by
- 438
- References
- 85
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.